Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1088606

Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study


Vrdoljak, Josip; Boban, Toni; Petrić Miše, Branka; Boraska Jelavić, Tihana; Bajić, Željko; Tomić, Snježana; Vrdoljak, Eduard
Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study // Japanese journal of clinical oncology, 49 (2019), 4; 347-353 doi:10.1093/jjco/hyz011 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1088606 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study

Autori
Vrdoljak, Josip ; Boban, Toni ; Petrić Miše, Branka ; Boraska Jelavić, Tihana ; Bajić, Željko ; Tomić, Snježana ; Vrdoljak, Eduard

Izvornik
Japanese journal of clinical oncology (0368-2811) 49 (2019), 4; 347-353

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Dose-dense, Chemotherapy, Ovarian cancer, Paclitaxel, Carboplatin
(dose-dense, chemotherapy, ovarian cancer, paclitaxel, carboplatin)

Sažetak
Background: The optimal first-line therapy of advanced ovarian cancer still remains questionable: standard paclitaxel–carboplatin (TC), dose-dense TC, intraperitoneal chemotherapy or TC plus bevacizumab. In this study, we present the real-life results of dose-dense treatment of the singleinstitution on Caucasian population. Methods: A retrospective cohort study was used on consecutive samples of 74 patients treated with the conventional 3-weekly TC protocol (2008–11) and on 70 treated with TC dose-dense protocol (2012–16). The primary endpoint of this study was overall survival (OS). Secondary endpoints were progression free-survival (PFS) and toxicity. We made adjustments for age, pathohistological type, tumor grade, stage and postoperative residual disease by Cox regression. Results: After adjustment for pre-planned clinical and sociodemographic factors, patients treated with dose-dense protocol showed a significantly lower hazard for dying from any cause, than patients treated with conventional protocol (HR = 0.50 ; 95% CI 0.26–0.98 ; P = 0.042). Median OS, at 60 months follow-up had not been reached in the dose- dense group, while in the standard treatment group was 48 months (95% CI 33–62). Unadjusted PFS was significantly longer in the dosedense group (HR = 0.58 ; 95% CI 0.38–0.88 ; P = 0.011), but not after the adjustment (P = 0.096). Generally, the level of toxicity was similar in both groups of patients. The need for blood transfusions and usage of filgrastim was significantly higher in the TC dd group. The incidence of neutropenia and thrombocytopenia Grade 3 or 4 were not significantly different in both regimens. Conclusions: Our retrospective study has shown the superior efficacy and comparable toxicity of dose- dense chemotherapy regimen over the conventional regimen in treatment of ovarian cancer on Caucasian population at a single-institution.

Izvorni jezik
Engleski



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Split

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Vrdoljak, Josip; Boban, Toni; Petrić Miše, Branka; Boraska Jelavić, Tihana; Bajić, Željko; Tomić, Snježana; Vrdoljak, Eduard
Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study // Japanese journal of clinical oncology, 49 (2019), 4; 347-353 doi:10.1093/jjco/hyz011 (međunarodna recenzija, članak, znanstveni)
Vrdoljak, J., Boban, T., Petrić Miše, B., Boraska Jelavić, T., Bajić, Ž., Tomić, S. & Vrdoljak, E. (2019) Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study. Japanese journal of clinical oncology, 49 (4), 347-353 doi:10.1093/jjco/hyz011.
@article{article, author = {Vrdoljak, Josip and Boban, Toni and Petri\'{c} Mi\v{s}e, Branka and Boraska Jelavi\'{c}, Tihana and Baji\'{c}, \v{Z}eljko and Tomi\'{c}, Snje\v{z}ana and Vrdoljak, Eduard}, year = {2019}, pages = {347-353}, DOI = {10.1093/jjco/hyz011}, keywords = {Dose-dense, Chemotherapy, Ovarian cancer, Paclitaxel, Carboplatin}, journal = {Japanese journal of clinical oncology}, doi = {10.1093/jjco/hyz011}, volume = {49}, number = {4}, issn = {0368-2811}, title = {Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study}, keyword = {Dose-dense, Chemotherapy, Ovarian cancer, Paclitaxel, Carboplatin} }
@article{article, author = {Vrdoljak, Josip and Boban, Toni and Petri\'{c} Mi\v{s}e, Branka and Boraska Jelavi\'{c}, Tihana and Baji\'{c}, \v{Z}eljko and Tomi\'{c}, Snje\v{z}ana and Vrdoljak, Eduard}, year = {2019}, pages = {347-353}, DOI = {10.1093/jjco/hyz011}, keywords = {dose-dense, chemotherapy, ovarian cancer, paclitaxel, carboplatin}, journal = {Japanese journal of clinical oncology}, doi = {10.1093/jjco/hyz011}, volume = {49}, number = {4}, issn = {0368-2811}, title = {Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study}, keyword = {dose-dense, chemotherapy, ovarian cancer, paclitaxel, carboplatin} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font